⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AMRX News
Amneal Pharmaceuticals, Inc. Class A Common Stock
Zambon annuncia il parere positivo del CHMP per Hopledo® (IPX203) nei pazienti adulti con Malattia di Parkinson e fluttuazioni motorie da moderate a severe
businesswire.com
AMRX
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
globenewswire.com
AMRX
Ritedose Commits to National "Hope Alliance" Campaign to Support Uninsured Patients
prnewswire.com
VTRS
AMRX
ARX
Ambros Therapeutics Appoints Cris Calsada as Chief Financial Officer and Claire Padgett, Ph.D., as SVP of Clinical Operations and Program Management
globenewswire.com
RPTX
AMRX
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
prnewswire.com
AMRX
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
globenewswire.com
AMRX
IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsight
globenewswire.com
AMRX
ARX
GSK
AZN
SNY
NVS
MRK
REGN
JNJ
PFE
BMY
LLY
VRTX
AMGN
ABBV
GILD
BIIB
CSL
AQST
RAPT
ALGT
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
globenewswire.com
AMRX
Metastatic HER2-Positive Breast Cancer Market Expected to Surge at a CAGR of 8.3% During the Forecast Period (2026–2036) Due to Advancing Targeted Treatments | DelveInsight
globenewswire.com
PFE
JNJ
AMRX
BOLT
BIIB
Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
globenewswire.com
AMRX